Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Advanced Cancer 6Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Malignancies Multiple 1Lung Neoplasms 1Head and Neck Neoplasms 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × linrodostat × Clear all
NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡